Earnings Week Ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and More
RSV Vaccine Market to Decline 64% on CDC Decision: Report
Biogen Analyst Ratings
10 Health Care Stocks Whale Activity In Today's Session
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
AbbVie Exits Alzheimer's Program on Lack of Differentiation
Unpacking the Latest Options Trading Trends in Amgen
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
Biogen-partnered Alzheimer's Therapy Fails to Clear EU Hurdle
Vertex Pharmaceuticals Analyst Ratings
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Sage Therapeutics Cut to Neutral at J.P. Morgan on Pipeline Concerns
Market Whales and Their Recent Bets on AMGN Options
This Is What Whales Are Betting On Gilead Sciences
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
AstraZeneca Slips Despite 2024 Guidance Raise on Medicines Demand